Decentralised clinical trials (DCTs) are transforming drug development as we know it. Democratising research, enhancing diversity, reducing participant burden, improving access, speeding up recruitment and optimising efficiencies. Coming of age during the pandemic era, DCTs sprang into action to deliver clinical trial continuity amidst global restrictions and lockdowns, introducing clinical trials into the homes of patients with innovative technology and pioneering distribution models.
But what’s next for DCTs? And how is direct to patient distribution supporting sponsors to maximise the transformative potential on offer?
Join Almac expert and Supply Chain Solutions Manager, David Ergott, on the 25 September 2024 for a deep dive into the realm of DCTs and the evolving role direct to patient distribution is playing in shaping a new, patient-focused chapter in drug development.
Register today and get set to journey through the evolution of direct to patient distribution by understanding the regulatory landscape and the role of a clinical Pharmacist. Explore the challenges that require careful navigation and hear expert insights surrounding the future landscape.
A thought leader in his field, David will guide delegates through the various direct to patient distribution models available. He’ll cover how these models can be crafted to cater to diverse programme requirements and harnessed in myriad ways, including strategically to support studies incorporating frequent dosing and/or remote monitoring and as contingency to safeguard supply during crises.
There’ll also be opportunity to learn best practices for implementing a direct to patient distribution approach as part of your DCTs. Followed by a live Q&A at the end of the presentation.
Key Learning Objectives
- Discover what a DCT is and the benefits of utilising a decentralised approach.
- Understand how direct to patient distribution supports DCTs.
- Learn from best practice examples for implementing direct to patient distribution.
- Explore the regulatory landscape and the role of Clinical Pharmacists.
